Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pioglitazone + dapagliflozin
- Development stage
- Unknown
- Lead developer
- Hamad Medical Corporation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This investigational combination therapy consists of two small molecule agents: dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and a low dose of pioglitazone, a thiazolidinedione. Developed by Hamad Medical Corporation, the combination is being evaluated in Phase 3 clinical trials for the treatment of heart failure with preserved ejection fraction (HFpEF) in patients with type 2 diabetes mellitus. Dapagliflozin works by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting osmotic diuresis, which has been shown to reduce the risk of heart failure hospitalization. Pioglitazone acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, improving insulin sensitivity and metabolic function. The combination aims to provide synergistic therapeutic benefits by addressing both the hemodynamic and metabolic components of heart failure in diabetic populations.
- Other names
- pioglitazone plus dapagliflozindapagliflozin + pioglitazonedapagliflozin plus pioglitazone
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on pioglitazone + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pioglitazone + dapagliflozin.